MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer.
In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >
Our lead investigational product candidate, AFREZZA®
MannKind has completed recruiting patients for the Affinity1 (Type 1) and Affinity2 (Type 2) clinical studies.
Read the press release here.